고셔병 시장 : 유형별, 진단 및 치료별, 최종 사용자별, 지역별(2026-2034년)

The global gaucher disease market size reached USD 1.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.76% during 2026-2034. Increasing number of patients suffering from Gaucher disease, extensive research and development (R&D) activities, and the easy availability of drugs represent some of the key factors driving the market.

Gaucher disease, also known as lysosomal storage disorder, is a rare genetic metabolic disorder that affects the ability of the body to break down and store fats. It is caused by glucocerebrosidase deficiency, which breaks down glucocerebroside fatty chemicals in the body. It is associated with an enlarged spleen and liver, anemia, easy bruising and bleeding, lung problems, fatigue, seizures, and bone abnormalities. It is diagnosed through various physical examinations, medical history, and laboratory tests, such as blood and imaging tests, and genetic testing to confirm the presence of a mutation in the gene. Gaucher disease can be treated using medications, injections, enzyme replacement therapy (ERT), bone marrow transplantation, and substrate reduction therapy (SRT), which aid in minimizing the pain associated with the symptoms and improve the quality of life.

GAUCHER DISEASE MARKET TRENDS:

At present, the increasing prevalence of genetic abnormalities among individuals and the rising number of patients suffering from Gaucher disease represent one of the major factors bolstering the market growth around the world. Moreover, the growing aging population that is more prone to developing these medical disorders is resulting in an increasing demand for Gaucher disease treatment. In addition, there is a rise in the implementation of health insurance policies that provide financial assistance for Gaucher disease treatment and reduce medical expenses. Apart from this, the growing awareness about Gaucher disease, its symptoms, diagnosis, and the easy availability of the treatment options is influencing the market positively. Furthermore, governments of numerous countries are investing in research and development (R&D) activities to study Gaucher disease and develop new treatments. They are also undertaking measures to offer quality healthcare facilities that are accessible to all. This, coupled with significant improvements in the diagnostic technologies, is creating a positive outlook for the market. Besides this, the rising awareness about the easy availability of ERT treatment alternatives like oral therapies that help break down glucocerebroside and reduce the accumulation is contributing to the growth of the market. They generally involve generic drugs that are readily available over the counter (OTC) and by prescription for relieving pain associated with Gaucher disease.

KEY MARKET SEGMENTATION:

Type Insights:

• Gaucher Disease Type 1
• Gaucher Disease Type 2
• Gaucher Disease Type 3
• Others

Diagnosis and Treatment Insights:

• Diagnosis
  • Physical Exam
  • Blood Tests
  • Imaging Tests
  • Preconception Screening and Prenatal Testing
  • Others
• Treatment
  • Surgery
  • Medication
  • Others

End User Insights:

• Hospitals
• Specialty Clinics
• Homecare

Regional Insights:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for Gaucher disease. Some of the factors driving the North America Gaucher disease market included increasing prevalence of genetic abnormalities, the presence of a well-established healthcare infrastructure, the integration of advanced medical technologies, etc.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global Gaucher disease market. Detailed profiles of all major companies have also been provided. Some of the companies covered include ISU Abxis Co. Ltd., Johnson & Johnson, Pfizer Inc., Protalix Biotherapeutics, Sanofi S.A, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Gaucher Disease Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Gaucher Disease Type 1
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Gaucher Disease Type 2
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Gaucher Disease Type 3
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

• 7.1 Diagnosis
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Physical Exam
    • 7.1.2.2 Blood Tests
    • 7.1.2.3 Imaging Tests
    • 7.1.2.4 Preconception Screening and Prenatal Testing
    • 7.1.2.5 Others
  • 7.1.3 Market Forecast
• 7.2 Treatment
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Surgery
    • 7.2.2.2 Medication
    • 7.2.2.3 Others
  • 7.2.3 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Specialty Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Homecare
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 ISU Abxis Co. Ltd.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Johnson & Johnson
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Pfizer Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Protalix Biotherapeutics
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Sanofi S.A
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Takeda Pharmaceutical Company Limited
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis